Education
About Us
Working with TipRanks
Follow Us
Sanara MedTech (SMTI)
:SMTI
SMTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.00 - $39.98
Previous CloseN/A
Volume5.72K
Average Volume (3M)22.68K
Market Cap
$303.23M
Enterprise Value$272.88M
Total Cash (Recent Filing)$731.85K
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Mar 26, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding8,741,161
10 Day Avg. Volume21,196
30 Day Avg. Volume22,678
Standard Deviation0.17
R-Squared0.17
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.88
Price to Cash Flow (P/CF)37.00
P/FCF Ratio25.20
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda-65.86
Forecast
1Y Price Target
$48.00Price Target Upside38.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Sanara MedTech News
PremiumCompany Announcements
Sanara MedTech Strengthens Leadership with New CFO Appointment
PremiumCompany Announcements
Sanara MedTech Secures U.S. Rights for OsStic
---
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth was driven primarily by increased sales of soft tissue repair products, including CellerateRX Surgical Activated Collagen and BIASURGE.
Strategic PartnershipsSanara entered an exclusive license and distribution agreement with Biomimetic Innovations Ltd for a breakthrough device, which could enrich Sanara’s existing surgical product offerings.
Bears Say
Sales NormalizationApproximately $1.8M of BIASURGE sales in 4Q24 was attributable to a unique situation (Hurricane Helene), and BIASURGE sales are expected to normalize in 1Q25.
---
Ownership Overview
52.74% Insiders
3.23% Mutual Funds
0.25% Other Institutional Investors
39.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $26.00 and its highest was $39.98 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $303.23M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is Mar 26, 2025 which is in 22 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on Nov 12, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.28.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is -0.12.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 8,741,161 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went up 7.572%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
---
Sanara MedTech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.00 (38.37% Upside)
$48.00 (38.37% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.76%
12-Months-Change
Fundamentals
Return on Equity
-19.89%
Trailing 12-Months
Asset Growth
17.32%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
---
SMTI Company Deck
---
SMTI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strategic investments, notably in ChemoMouthpiece, alongside ongoing expansion efforts. However, these positives were tempered by a substantial net loss increase, higher SG&A expenses, and rising interest costs.Read More>---
SMTI Stock 12 Month Forecast
Average Price Target
$48.00
▲(38.37% Upside)
Technical Analysis
Best Analysts Covering SMTI
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+15.00%
reiterated a buy rating last month
Copying Ross Osborn's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +15.00% per trade.
---